Search

Your search keyword '"Hofmann W. -K."' showing total 504 results

Search Constraints

Start Over You searched for: Author "Hofmann W. -K." Remove constraint Author: "Hofmann W. -K."
504 results on '"Hofmann W. -K."'

Search Results

1. The new WHO 2022 and ICC proposals for the classification of myelodysplastic neoplasms. Validation based on the Düsseldorf MDS Registry and proposals for a merged classification

2. Comprehensive mutational analysis of primary and relapse acute promyelocytic leukemia

5. Topic: AS06-Prognosis/AS06a-Prognostic factors of outcome and risk assessment: IMPROVED PROGNOSIS OF PATIENTS WITH MDS OVER FOUR DECADES: ANALYSIS FROM THE GERMAN MDS REGISTRY

6. Topic: AS04-MDS Biology and Pathogenesis/AS04c-MDS Mouse models (GEMMS, PDX): OPTIMIZATION OF MDS PATIENT-DERIVED XENOGRAFT (PDX) MODELS BY COMPARISON OF NSG AND NBSGW MICE

7. 5-AZACYTIDINE IN COMBINATION WITH A NOVEL PAN-LYSYL OXIDASE INHIBITOR SYNERGISTICALLY RESTORES ERYTHROPOIESIS IN MYELODYSPLASTIC MALIGNANCIES

8. Topic: AS06-Prognosis/AS06a-Prognostic factors of outcome and risk assessment: INTERMEDIATE RISK KARYOTYPE BY IPSS-R CAN BE SEPARATED INTO 5 PROGNOSTICALLY DISTINCT SUBGROUPS IN MDS PATIENTS

9. Topic: AS06-Prognosis/AS06b-Predictive factors of response to treatment: AUGMENTED ACTIVITY OF THE ALVOCIDIB AND 5-AZACYTIDINE COMBINATION IN MYELODYSPLASTIC NEOPLASMS IS ASSOCIATED WITH THE PRESENCE OF ASXL1 MUTATIONS

10. Topic: AS06-Prognosis/AS06a-Prognostic factors of outcome and risk assessment: COMPARISON OF PROGNOSTICATION BY IPSS-M, IPSS-R AND AIPSS-MDS IN THE CONTEXT OF LIMITED AVAILABILITY OF MOLECULAR DATA IN DAILY CLINICAL PRACTICE

11. Myelodysplastische Syndrome

12. Diagnosis of invasive fungal infections in haematological patients by combined use of galactomannan, 1,3-β-D-glucan, Aspergillus PCR, multifungal DNA-microarray, and Aspergillus azole resistance PCRs in blood and bronchoalveolar lavage samples: results of a prospective multicentre study

13. P103 - Topic: AS06-Prognosis/AS06b-Predictive factors of response to treatment: AUGMENTED ACTIVITY OF THE ALVOCIDIB AND 5-AZACYTIDINE COMBINATION IN MYELODYSPLASTIC NEOPLASMS IS ASSOCIATED WITH THE PRESENCE OF ASXL1 MUTATIONS

14. P094 - Topic: AS06-Prognosis/AS06a-Prognostic factors of outcome and risk assessment: INTERMEDIATE RISK KARYOTYPE BY IPSS-R CAN BE SEPARATED INTO 5 PROGNOSTICALLY DISTINCT SUBGROUPS IN MDS PATIENTS

15. P089 - Topic: AS06-Prognosis/AS06a-Prognostic factors of outcome and risk assessment: IMPROVED PROGNOSIS OF PATIENTS WITH MDS OVER FOUR DECADES: ANALYSIS FROM THE GERMAN MDS REGISTRY

16. P090 - Topic: AS06-Prognosis/AS06a-Prognostic factors of outcome and risk assessment: COMPARISON OF PROGNOSTICATION BY IPSS-M, IPSS-R AND AIPSS-MDS IN THE CONTEXT OF LIMITED AVAILABILITY OF MOLECULAR DATA IN DAILY CLINICAL PRACTICE

18. O12 - 5-AZACYTIDINE IN COMBINATION WITH A NOVEL PAN-LYSYL OXIDASE INHIBITOR SYNERGISTICALLY RESTORES ERYTHROPOIESIS IN MYELODYSPLASTIC MALIGNANCIES

22. Prevalence, clonal dynamics and clinical impact of TP53 mutations in patients with myelodysplastic syndrome with isolated deletion (5q) treated with lenalidomide: results from a prospective multicenter study of the german MDS study group (GMDS)

25. P771: PROGNOSTIC CHARACTERISTICS OF PATIENTS WITH MDS WITH ABERRATIONS OF CHROMOSOME 5. DATA FROM THE DÜSSELDORF MDS REGISTRY

30. Therapy of Advanced MDS, AML Evolving from MDS, or Secondary AML with Idarubicin Ara-C, VP-16, Followed by G-CSF-Priming Exhibits High Remission Rate

31. Chemotherapy with Idarubicin, Ara-C,VP-16, Amsacrine, Followed by G-CSF and Maintenance Immunotherapy with Interleukin-2 for Patients with High-Risk Acute Myeloid leukemia: a 3-Years Follow-Up

32. Velocity of early BCR-ABL transcript elimination as an optimized predictor of outcome in chronic myeloid leukemia (CML) patients in chronic phase on treatment with imatinib

37. Secondary malignancies in chronic myeloid leukemia patients after imatinib-based treatment: long-term observation in CML Study IV

39. O02 - Topic: AS08-Treatment/AS08e-New developments - Preclinical studies: A PRE-CLINICAL PATIENT-DERIVED XENOGRAFT MODEL OF MYELODYSPLASTIC SYNDROMES DEMONSTRATES EFFICACY AND SAFETY OF ELTROMBOPAG

42. Identification of invasive fungal diseases in immunocompromised patients by combining an Aspergillus specific PCR with a multifungal DNA-microarray from primary clinical samples

44. Topic: AS08-Treatment/AS08e-New developments - Preclinical studies

45. Topic: AS04-MDS Biology and Pathogenesis/AS04i-Microenvironment and stem cell niche

48. Results from a 1-year, open-label, single arm, multi-center trial evaluating the efficacy and safety of oral Deferasirox in patients diagnosed with low and int-1 risk myelodysplastic syndrome (MDS) and transfusion-dependent iron overload

50. Survival, prognostic factors and rates of leukemic transformation in 381 untreated patients with MDS and del(5q): A multicenter study

Catalog

Books, media, physical & digital resources